NO914091L - Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase - Google Patents

Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase

Info

Publication number
NO914091L
NO914091L NO91914091A NO914091A NO914091L NO 914091 L NO914091 L NO 914091L NO 91914091 A NO91914091 A NO 91914091A NO 914091 A NO914091 A NO 914091A NO 914091 L NO914091 L NO 914091L
Authority
NO
Norway
Prior art keywords
hiv
reverstranscriptase
hydroxylated
inhibitors
procedure
Prior art date
Application number
NO91914091A
Other languages
English (en)
Other versions
NO914091D0 (no
Inventor
Shieh-Shung Tom Chen
Annjia Hsu
George A Doss
Mark E Goldman
Suresh K Balani
Anthony D Theoharides
Jr Jacob M Hoffman
Steven M Pitzenberger
Harri G Ramjit
Laura R Kauffman
Byron H Arison
Walfred S Saari
Clarence S Rooney
John S Wai
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO914091D0 publication Critical patent/NO914091D0/no
Publication of NO914091L publication Critical patent/NO914091L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Nye forbindelser med formelen. Rj eller Reller begge er substituert minst én gang med OH; X er NR, 0, S,eller oksimido eller én til fem halogenatomer, C^-alkyltio, -alkyl-sulfinyl, -alkylsulfonyl, -alkoksy, -alkoksykarbonyl, cyan eller aryl; eller Rs og R, kan sammen danne en cykloalkylring med 5-7 ringatomer; eller Rj og Rkan sammen danne en cykloalkylring med 5-7 ringatomer; og Rog R, er H, C..-alkyl, C..-alkenyl, C..-cykloalkyl;. er aryl eller en. heterocyklisk rest som kan være substituert, med det forbehold at den heterocykliske rest ikke er ftalimid, eller farmasøytisk akseptabelt salt eller ester derav.Forbindelsene inhiberer HIV-reverstranskriptase og kan anvendes ved forhindring eller behandling av infeksjon med HIV og ved behandling av AIDS, eventuelt i kombinasjon med andre antivirusmidler, antiinfeksJonsmidler, immunomodulatorer, antibiotika eller vaksiner.
NO91914091A 1990-10-18 1991-10-17 Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase NO914091L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59996890A 1990-10-18 1990-10-18
US71232691A 1991-06-07 1991-06-07
US76958091A 1991-10-07 1991-10-07

Publications (2)

Publication Number Publication Date
NO914091D0 NO914091D0 (no) 1991-10-17
NO914091L true NO914091L (no) 1992-04-21

Family

ID=27416795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914091A NO914091L (no) 1990-10-18 1991-10-17 Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase

Country Status (10)

Country Link
EP (1) EP0481802A1 (no)
JP (1) JPH05170740A (no)
KR (1) KR920007998A (no)
AU (1) AU8596191A (no)
CA (1) CA2053512A1 (no)
IE (1) IE913647A1 (no)
IL (1) IL99731A0 (no)
MX (1) MX9101634A (no)
NO (1) NO914091L (no)
PT (1) PT99260A (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238576A (en) * 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof
DE69315920T2 (de) * 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
US5604095A (en) * 1994-07-22 1997-02-18 Cancer Therapy & Research Center Unsymmetrically linked bisnaphthalimides as antitumor agents
US5561042A (en) * 1994-07-22 1996-10-01 Cancer Therapy And Research Center Diamine platinum naphthalimide complexes as antitumor agents
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
GB0212971D0 (en) * 2002-06-06 2002-07-17 Karobio Ab Novel compounds
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2007027729A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
AU2006285038A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
JP5112317B2 (ja) * 2005-08-29 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
WO2008016522A2 (en) * 2006-07-24 2008-02-07 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
PL2797416T3 (pl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
HUE062424T2 (hu) 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
JPS5583786A (en) * 1978-12-20 1980-06-24 Dainippon Pharmaceut Co Ltd Diazepine derivative and its preparation
US4461901A (en) * 1983-03-04 1984-07-24 American Home Products Corporation Pyridyl containing 1,2-benzisothiazole-3-amine derivatives
US5003055A (en) * 1987-09-25 1991-03-26 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Anthracycline derivatives having inhibitory activity against reverse transcriptase of human immunodeficiency virus
EP0403535A1 (en) * 1988-03-01 1990-12-27 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
NZ238576A (en) * 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
MX9101634A (es) 1992-06-05
KR920007998A (ko) 1992-05-27
JPH05170740A (ja) 1993-07-09
IE913647A1 (en) 1992-04-22
NO914091D0 (no) 1991-10-17
CA2053512A1 (en) 1992-04-19
IL99731A0 (en) 1992-08-18
EP0481802A1 (en) 1992-04-22
AU8596191A (en) 1992-08-13
PT99260A (pt) 1992-09-30

Similar Documents

Publication Publication Date Title
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
LU90709I2 (fr) Efavirenz optionnellement sous forme d'un sel pharmaceutiquement acceptable
EA200400585A1 (ru) N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
RU94027563A (ru) Соединения-ингибиторы вич протеазы, их использование для лечения спида, форикомпозиция
ATE175412T1 (de) Hiv-protease-inhibitoren
DK91690D0 (da) Anvendelse af adamantan-derivater til fremstilling af terapeutiske praeparater til behandling af ischaemi
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
MY206712A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
NO953876L (no) HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS
SE8802790D0 (sv) Tripeptider med immunostimulerande och metastasforhindrande verkan
ATE215952T1 (de) Hiv-proteaseinhibitoren
NO962000L (no) Prolegemidler av en inhibitor av HIV-protease
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
FI911875A0 (fi) Kirala 2-(fosfonometoxi) propylguaniner som antivirala aemnen.
ATE122562T1 (de) Derivate von penciclovir zur behandlung von hepatitis-b-infektionen.
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
NO20002481L (no) Kombinasjonsterapi for behandling av AIDS
ES8602723A1 (es) Un procedimiento para la preparacion de nuevas n-bencil-propilaminas sustituidas.
NO970632L (no) HIV-proteaseinhibitorkombinasjon
DK0728002T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 7-infektioner
ES2108254T3 (es) Composicion del inhibidor de infeccion con virus del sida.
DK0728001T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 6-infektioner
NO944208L (no) Nye kinazoliner som inhibitorer av HIV-reverstranskriptase
FI970565A0 (fi) HIV-proteaasia inhiboiva yhdistelmä
NO931337L (no) Forbindelser og fremgangsmaater for inhibering av hiv og beslektede virus